Similar articles

• Influence of antilymphocyte globulin upon the incidence of malignancies after kidney transplantation.

  Luciani J, Benalia H, Bitker MO, Mouquet C, Chartier-Kastler E, Ourhama S, Jacobs C, Chatelain C, Viars P. Luciani J, et al. Transplant Proc. 1993 Jun;25(3):2302. Transplant Proc. 1993. PMID: 8516907 Clinical Trial. No abstract available.
• Cyclosporine, combination immunosuppression, and posttransplant diabetes mellitus.

  Boudreaux JP, McHugh L, Canafax DM, Asher N, Sutherland DE, Payne W, Simmons RL, Najarian JS, Fryd DS. Boudreaux JP, et al. Transplant Proc. 1987 Feb;19(1 Pt 2):1811-3. Transplant Proc. 1987. PMID: 3079040 Clinical Trial. No abstract available.
• Myocardial changes and kidney transplantation. Lesions in patients receiving immunosuppressive therapy.

  Chatty ME, Deodhar SD. Chatty ME, et al. Arch Pathol. 1969 Dec;88(6):602-8. Arch Pathol. 1969. PMID: 4982499 No abstract available.
• Nursing implications of immunosuppression in transplantation.

  Shaefer M, Williams L. Shaefer M, et al. Nurs Clin North Am. 1991 Jun;26(2):291-314. Nurs Clin North Am. 1991. PMID: 1904575 Review.
• Immunology in neoplasia relating to diagnosis, therapy and transplantation. Immunosuppression and oncogenesis.

  Cerilli J, Hattan D. Cerilli J, et al. Am J Clin Pathol. 1974 Aug;62(2):218-23. doi: 10.1093/ajcp/62.2.218. Am J Clin Pathol. 1974. PMID: 4602088 Review. No abstract available.